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Abstract
High extracellular matrix (ECM) content in solid cancers impairs
tumour perfusion and thus access of imaging and therapeutic
agents. We have devised a new approach to degrade tumour ECM,
which improves uptake of circulating compounds. We target the
immune-modulating cytokine, tumour necrosis factor alpha
(TNFa), to tumours using a newly discovered peptide ligand
referred to as CSG. This peptide binds to laminin–nidogen
complexes in the ECM of mouse and human carcinomas with little
or no peptide detected in normal tissues, and it selectively delivers
a recombinant TNFa-CSG fusion protein to tumour ECM in tumour-
bearing mice. Intravenously injected TNFa-CSG triggered robust
immune cell infiltration in mouse tumours, particularly in the
ECM-rich zones. The immune cell influx was accompanied by
extensive ECM degradation, reduction in tumour stiffness, dilation
of tumour blood vessels, improved perfusion and greater intratu-
moral uptake of the contrast agents gadoteridol and iron oxide
nanoparticles. Suppressed tumour growth and prolonged survival
of tumour-bearing mice were observed. These effects were attain-
able without the usually severe toxic side effects of TNFa.
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Introduction
A dense network of highly disorganised ECM is the central feature
of desmoplastic tumours and often encountered in aggressive and
treatment-resistant cancers (Pickup et al, 2014). Tumour ECM is
made of overproduced scaffolds of collagen, non-collagenous glyco-
proteins and glycosaminoglycans (Mouw et al, 2014). Collectively,
these ECM components represent an obstructive physical barrier
that determines how migrating cells and circulating compounds
enter and exit a tumour. In diagnostic and therapeutic settings, the
ECM barrier restricts penetration, and thereby tumour uptake of
various imaging agents and anti-cancer therapeutics (Hellebust &
Richards-Kortum, 2012; Salmon et al, 2012; Choi et al, 2013).
Destroying the fibrotic ECM barrier to increase the vulnerability of a
tumour presents a compelling adjuvant strategy. For instance, ECM
can be disrupted by employing locally injected or ectopically
expressed enzymes (Guedan et al, 2010; Caruana et al, 2015),
systemic application of modified hyaluronidase (PEGPH20) (Proven-
zano et al, 2012), fibrinolytic therapy with tissue plasminogen acti-
vator (Kirtane et al, 2017), treatment with inhibitors of ECM
production (Olive et al, 2009; Diop-Frimpong et al, 2011; Vennin
et al, 2017) or physical means, such as photothermal therapy
(Marangon et al, 2017).
Thus far, however, existing approaches lack the specificity to
target and degrade tumour ECM and, therefore, tend to cause
systemic toxicity (Kirtane et al, 2017). Moreover, some of the strate-
gies used to degrade or reduce tumour ECM have also been impli-
cated in promoting metastases (Ozdemir et al, 2014; Sevenich &
Joyce, 2014; Schmaus & Sleeman, 2015; Rath et al, 2017). Thus,
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new approaches to dealing with the ECM barrier in tumours are
needed. We have devised a strategy that is based on targeting of an
immune-modulating cytokine into tumour ECM. Screening of phage-
displayed peptide libraries in live mice has been used to identify
peptides that specifically recognise tumours (Ruoslahti, 2016). The
tumour-homing peptides identified in this manner can be used in
selective delivery of payloads to tumours. For example, targeted
delivery of cytokines into tumours can improve therapeutic
outcomes (Hamzah et al, 2008; Johansson et al, 2012; Johansson-
Percival et al, 2015). Here, we identified a peptide that specifically
recognises tumour ECM and used it to target a cytokine to the ECM.
TNFa is a pleiotropic cytokine known to promote innate and
adaptive immune responses (Talmadge et al, 1987). It can stimu-
late multiple types of immune cells to secrete proteases that are
capable of degrading ECM (Vaday et al, 2000; Melamed et al,
2006). An in vitro study shows that TNFa bound to fibronectin in
ECM attracts monocytes and triggers their activation into MMP9-
secreting cells (Vaday et al, 2000). We hypothesised that TNFa,
when specifically targeted to tumour ECM, may have similar
effects, leading to ECM degradation and enhanced penetration of
compounds to tumours. Here, we demonstrate that TNFa fused to
a new tumour ECM-recognising peptide specifically accumulates in
desmoplastic tumours, increasing immune cell accumulation and
ECM degradation.
Results
Identification and analysis of a tumour ECM-binding peptide
We designed a phage library screening protocol aimed at identifying
peptides specific for tumour ECM. The screen consisted of an initial
in vitro biopanning of a library of random seven-amino acid
peptides flanked by a cysteine residue on each side (general struc-
ture: CX7C) on MatrigelTM. Matrigel is an ECM preparation derived
from a mouse tumour that produces copious amounts of basement
membrane (BM)-type ECM consisting primarily of laminin, nidogen-
1 (also known as entactin) and collagen IV. There are also traces of
heparan sulphate proteoglycan (perlecan), along with some growth
factors. The enriched phage pool from 3 in vitro rounds was subse-
quently subjected to 4 rounds of in vivo screening in mice bearing
MDA-MB-435 human breast cancer xenograft tumours. A 9-amino
acid peptide, CSGRRSSKC (termed CSG), and its variants were
present in multiple copies in the final phage pool (Appendix Fig
S1A–D). CSG was selected for further study.
We compared the binding of synthetic carboxyfluorescein
(FAM)-labelled CSG to tumour sections. Appendix Fig S1E and F
shows robust binding to sections of neuroendocrine pancreatic
tumours from genetically engineered RIP1-Tag5 mice which are
strongly fibrotic (Ganss & Hanahan, 1998). CREKA, a previously
identified peptide that binds to fibrin deposited on the vessel walls
of tumour vessels and to tumour stroma (Simberg et al, 2007),
showed weaker (about 10-fold less) binding which was essentially
restricted to tumour vessels, and there was no detectable binding of
a peptide with no tumour-binding activity (ARA). When injected
intravenously (i.v.) into tumour-bearing mice, CSG specifically
accumulated in orthotopically implanted murine 4T1 breast and
RIP1-Tag5 tumours (Fig 1). Excluding the kidneys where circulating
peptides are excreted, normal organs showed only background fluo-
rescence (Fig 1A). The specificity of the tumour accumulation was
confirmed by histological detection and quantification of FAM-
peptide homing using an antibody against fluorescein (Fig 1B and
C). The accumulation of CSG in these tumours was at least 10- to
15-fold higher than in the normal tissues. CSG also accumulated in
tumours in other mouse models, including the ALB-Tag hepatocellu-
lar carcinoma (HCC) (Ryschich et al, 2006), MMTV-PyMT breast
carcinoma and transplanted CT26 colon carcinoma (Appendix Fig
S1G).
To determine whether CSG also recognises human tumours, we
assessed FAM-CSG binding on fresh biopsies of primary human
breast carcinomas from seven mastectomy patients. CSG bound
selectively in all tumour specimens (Figs 1D and E, and EV1A),
whereas there was negligible binding to the adjacent normal breast
tissue (Fig 1D). The FAM-CSG binding was inhibited by unlabelled
CSG, and the ARA control peptide showed no binding to the
tumours (Figs 1D and E, and EV1A). CSG-specific tumour binding
was also detected on fresh biopsies of primary human pancreatic
adenocarcinoma and HCC from three pancreatectomy and hepatec-
tomy patients, respectively (Fig EV1B). Therefore, CSG binding is
conserved in human fibrotic cancers.
As CSG was first isolated based on its in vitro binding to
Matrigel, we used a CSG affinity matrix to isolate the CSG target
molecule from a dilute solution of Matrigel. Elution of the affinity
matrix with soluble CSG peptide produced several bands, which
were identified by mass spectrometry as laminin subunits alpha-1
and gamma-1, and nidogen-1. These proteins were absent in eluates
▸Figure 1. CSG specifically recognises mouse and human tumours, and binds to ECM.A–C Mice bearing orthotopically implanted 4T1 breast cancers and RIP1-Tag5 (RT5) tumours were i.v. injected with 0.1 lmol of FAM-CSG, and tissues were collected
after 1-h circulation. (A) Photographic image of tissues from 4T1 tumour-bearing mouse under bright light and UV illuminator. (B and C) Distribution of FAM-CSG
in different tissues including tumours (4T1 T and RT5 T), kidney (K), vertebrae (V), lung (LG), liver (LV), intestine (I), muscle (MU), spleen (SP), heart (H), pancreas (P),
brain (B), lymph node (LN) and skin (SK), detected by immunoperoxidase staining with anti-FITC antibody. Representative staining (brown) is shown for each tissue
in (B) and as mean  SEM of percentage area per tissue section stained with anti-FITC antibody (n = 3; *P < 0.05 and **P < 0.005, tumour compared to other
tissues except kidney by one-way ANOVA test with Tukey’s correction) in (C). Scale bars: 100 lm.
D, E Human breast tumour (Hu BT) and normal breast tissues (Hu NB): 8-lm serial tissue sections were incubated for 30 min with 1 lM FAM-CSG or FAM-ARA, in the
presence or absence of 1 mM unlabelled CSG peptide. CSG (brown) was detected as in panels (B and C). (D) Representative micrographs of corresponding tissues
stained with anti-FITC antibody (brown) are shown for an individual patient sample. Scale bars: 150 lm. (E) Bar charts show mean  SEM of percentage area per
tissue section stained with anti-FITC antibody (N = 4 Hu NB and N = 7 Hu BT; ***P < 0.001 and ****P < 0.0001 by one-way ANOVA test with Tukey’s correction).
Source data are available online for this figure.
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obtained with the CREKA control peptide but appeared upon subse-
quent elution of the same matrix with CSG (Fig 2A). These results
indicate that the target of CSG is laminin–nidogen-1, which exists as
a complex in ECM (Timpl et al, 1990). We next studied the expres-
sion of laminin and nidogen-1, as well as collagen IV, the third
member of the basement membrane complex, in tumours. The three
A
D E
B C
Figure 2. CSG specifically binds tumour ECM with affinity to laminin–nidogen-1 complex.
Matrigel extract was fractionated by affinity chromatography on CSG-coupled columns. Bound proteins were eluted with 2 mM CSG or control CREKA peptide solutions and
separated by sodium dodecyl sulphate–polyacrylamide gel electrophoresis.
A Top: Silver staining shows multiple bands in the Matrigel extract (lane 1), laminin–nidogen-1 complex (lane 2) and purified laminin (lane 3), in comparison with 4
bands eluted with CSG peptide which did not appear in the first CSG elution (lane 4) but appeared in eluted fractions 2 (lane 5) and 3 (lane 6). These bands were no
longer visible in subsequent elution (lane 7). Bottom: Silver staining shows the absence of bands when CSG-coupled column was eluted with the control CREKA
peptide (lanes 1–3); subsequent elution of the column with the CSG peptide shows the 4 previously shown bands (lane 5). The 4 bands (top gel, lanes 5 and 6) were
identified by mass spectrometry as laminin subunit a-1 (Lama-1), laminin subunit c-1 (Lamc-1) and 2 nidogen-1 bands of 140 and 110 kDa.
B Normal pancreas from a C3H mouse (N Pan) and a RIP1-Tag5 tumour (RT5 T) were stained for the indicated ECM components. Representative micrographs are
shown in the top panel. Bar graphs in the bottom panel show quantification of the area positive for each ECM protein (mean  SEM; n = 3, *P < 0.05, **P < 0.005
and ***P < 0.001 by multiple t-tests).
C Tissues as shown in (B) were stained for laminin (lam, green) and blood vessels (CD31, red). Representative micrographs are shown. The bar graph depicts the ratio of
laminin over CD31 staining (mean  SEM; n = 5, **P < 0.005 by Student’s t-test). Arrows: areas positive for laminin expression but lack CD31 staining.
D Representative micrograph of a RIP1-Tag5 tumour (T) with normal pancreas (N Pan) showing CSG binding (green; in vitro binding was performed as indicated in
Appendix Fig S1E), laminin staining (lam; red) and CSG–laminin co-localisation (yellow).
E Co-staining analysis of in vitro bound CSG or CREKA (green) compared to indicated ECM markers or CD31+ tumour blood vessels (red). Representative micrographs
(left) and corresponding bar graphs (right) show co-localisation of indicated markers with CSG or CREKA (mean  SEM; n = 4, ****P < 0.001 by one-way ANOVA test
with Tukey’s correction).
Data information: Scale bars for (B, C and E): 50 lm. Scale bars (D): 200 lm.
Source data are available online for this figure.
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proteins co-localised in all tissues; however, their abundance was
greater in tumours than in normal tissues (Figs 2B and EV2A). As
indicated by co-staining for laminin and the blood vessel marker
CD31 (Fig 2C), laminin in normal mouse envelops the blood vessels
as part of the basement membrane complex. In contrast, in tumours
the basement membrane complex showed widespread expression
separate from the vessels (Fig 2C) and showed strong overlaps with
fibrillar collagens (collagen I and trichrome staining; Fig EV2B and
C). These results show that tumour ECM differs from normal ECM
in abundance and location.
FAM-CSG binding on tissue sections in vitro correlated with the
location of laminin, nidogen-1, collagen IV and collagen I but not
CD31+ blood vessels in mouse and human tumours and was negli-
gible in the basement membrane of normal tissues (Figs 2D and E,
and EV2D–F). CSG binding also showed some co-localisation with
ER-TR7, an antigen that recognises reticular fibroblasts and fibres,
but mostly in non-cellular ECM (Fig EV2F). Consistent with the
affinity pulldown results, CREKA showed only limited co-localisa-
tion with laminin (Fig 2E), indicating that CSG binding to laminin–
nidogen complex in tumour sections is specific. To investigate
further the source of tumour ECM recognised by CSG, we assessed
CSG binding in cultured 4T1 cells and bTC-C3H tumour cells
derived from RIP-Tag mice. Laminin expression and CSG binding
were most pronounced in 4T1 cells (Fig EV2G). bTC-C3H tumour
cells did not produce laminin and bind CSG (Fig EV2G), indicating
that the ECM complexes that bound CSG in RIP1-Tag5 tumours
(Fig 2D and E) were mainly stroma-associated.
Immune-enhancing effects of TNFa-CSG
To evaluate CSG as a carrier molecule for TNFa delivery to tumour
ECM, we produced bacterial recombinant TNFa with carboxy-term-
inal CSG peptide (molecular weight 18.9 kDa) (Appendix Fig S2A).
The fusion protein was biologically active as shown by induction
of VCAM-1 expression in cultured brain endothelial cells
(Appendix Fig S2B). Fluorescein-labelled TNFa-CSG, unlike TNFa,
selectively homed to tumour matrix in vivo (Appendix Fig S2C), in
the same manner as free CSG peptide (Fig 1).
TNFa-CSG was used in this study at a therapeutic dose range of
2–10 lg. Even at the highest dose (10 lg i.v. injection/day for 5
consecutive days), it was well tolerated in mice and did not reduce
animal body weights (Appendix Fig S2D). In contrast, the untar-
geted TNFa is lethally toxic at 10 lg (Cauwels et al, 1995; Marino
et al, 1997). Quantification of plasma C-reactive protein (CRP), a
marker for acute and chronic inflammation, showed that a single
dose of 10 lg untargeted TNFa significantly elevated plasma CRP in
healthy animals, whereas TNFa-CSG, given at the same dose once
or five times on consecutive days, did not significantly raise plasma
CRP levels (Appendix Fig S2E).
To evaluate the effects of TNFa-CSG on tumours, we focused on
the RIP1-Tag5 and 4T1 models because these tumours have different
levels of immune infiltrates but share abundant ECM and thus CSG
targets (Fig 1). In RIP1-Tag5 tumours, which were devoid of
immune infiltrates, treatment with TNFa-CSG (5 daily i.v. injections
of 2 or 5 lg) caused a significant influx of CD8+ and CD4+ T cells
and macrophages (Fig 3A). Moreover, CD8+ T cells selectively
accumulated in ECM-rich zones in the TNFa-CSG-treated tumours
(Fig EV3A). In contrast, our previously described TNFa fused to the
vessel-targeting peptide RGR (Hamzah et al, 2008; Johansson et al,
2012) at similar total doses caused immune cell infiltration around
tumour blood vessels (Fig EV3B).
In addition, in 4T1 tumours with pre-existing immune infiltrates,
we compared the effect of TNFa and TNFa-CSG on immune cell
infiltration at the maximally tolerated dose for TNFa (5 daily injec-
tions of 0.5 lg). At 0.5 lg, TNFa-CSG led to a significant increase in
intratumoral CD8+ T cells and macrophages (CD11b+ F480+
Ly6G) but reduced the population of tumour myeloid-derived
suppressor cells (CD11b+ F480 Ly6G+) (Fig EV3C). TNFa had no
effect on intratumoral T cells or myeloid-derived suppressor cells,
although an increase in macrophage level was also observed
(Fig EV3C). In addition to RIP1-Tag5 and 4T1 tumours, TNFa-CSG
(5 daily i.v. injections of 5 lg) also improved immune T-cell infiltra-
tion into ALB-Tag HCC (Fig EV3D). Therefore, ECM targeting of
TNFa, in contrast to unconjugated TNFa, attracts T cells into the
tumour microenvironment irrespective of tissue phenotypes, with-
out inducing systemic toxicity.
Overexpression of proteases, and reduced ECM content and
stiffness in response to TNFa-CSG
Having shown that TNFa-CSG attracts immune cells to tumour
ECM, we explored their potential role in tumour matrix degrada-
tion. Since previous in vitro studies showed that TNFa stimulates
monocytes to secrete MMP9 (Vaday et al, 2000), we first profiled
protease expression by immune cells in response to TNFa-CSG
treatment. Immune cells from 4T1 tumours of mice treated with
TNFa-CSG or CSG were separated by FACS into CD45+/CD11b
and CD45+/CD11b+ cells, and expression of various proteases
known to degrade ECM (Sorokin, 2010; Sevenich & Joyce, 2014)
was analysed. Tumour CD45+/CD11b cells from mice treated
with TNFa-CSG expressed twofold to 20-fold higher levels of
mRNAs for multiple proteases than cells from the CSG-treated
tumours. In particular, the mRNA transcripts including uPA,
MMP2, MMP3, MMP9, MMP12, MMP14 and cathepsin L were
significantly increased at 10 lg of TNFa-CSG (Fig 3B). TNFa-CSG
treatment did not affect protease gene expression in tumour
CD11b+ cells or in cultured 4T1 tumour cells (with the exception
of MMP3) (Fig EV4A). Protein-level analysis of MMP9 and MMP12
release by CD4+ T cells and cathepsin L by CD8+ T cells showed
that TNFa-CSG specifically induced release of these proteases
(Fig 3C). CD11b+ cells inherently secreted high levels of
proteases, especially MMP9 and MMP12 (Fig 3C). Thus, the accu-
mulation of these cells (Figs 3A and EV3) in response to TNFa-
CSG may also contribute to increased expression of proteases in
the tumours.
Immunostaining analysis of ECM proteins in TNFa-CSG-treated
RIP1-Tag5 tumours showed significantly reduced levels of laminin,
nidogen-1 and collagen IV (Fig 4A and B), whereas treatment with
the CSG peptide, or with the blood vessel-targeted TNFa-RGR,
(Johansson et al, 2012) had no effect (Fig 4A and B). TNFa-CSG
treatment also reduced other tumour ECM components, which
included fibrillar collagens (stained with picrosirius red), collagen I,
perlecan (HSPG2) and fibronectin (Fig EV4B). The number of stro-
mal content stained with ER-TR7 antibody was also significantly
reduced (Fig EV4B). T-cell infiltration is only observed in tumour
and not in the surrounding tissue (Fig EV5A). Thus, ECM content in
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normal exocrine tissue surrounding the tumours was unaffected by
TNFa-CSG treatment (shown for laminin in Fig EV5A). Interest-
ingly, the reduction in ECM content in response to TNFa-CSG treat-
ment was positively correlated with immune cell infiltration in the
RIP1-Tag5 tumours (Fig 4C and D), supporting the notion that the
immune cell proteases degrade the ECM.
Tissue stiffness is a hallmark of solid tumours and a direct
function of ECM content/properties (Pickup et al, 2014). Increased
stiffness reflects the pathological state of malignant tissue that
influences cell behaviour in tumour (Lampi & Reinhart-King,
2018). Quantitative micro-elastography was employed to measure
structural heterogeneity of tumour stiffness (Kennedy et al,
A
B
C
Figure 3.
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2015a). The mean tumour stiffness remains unchanged in
response to TNFa-CSG treatment (Fig 5; Appendix Table S1).
However, control tumours showed greater structural heterogeneity
of tissue stiffness displaying more frequent “hotspots” of stiffest
areas (exceeded 100 kPa) and also some areas in the softest cate-
gory (under 10 kPa). TNFa-CSG treatment resulted in a more
homogenous distribution of tumour stiffness, with significantly
reduced stiffness variability in the range well below 100 kPa
(Fig 5A–D). Stiffness measurements also demonstrated reduced
tumour stiffness correlated with TNFa-CSG-induced ECM loss
(Figs 5E and EV5B).
Reduced ECM content and tumour stiffness correlate with
improved tumour perfusion and uptake of nanoparticle
contrast agents
Lowering ECM content is known to lead to improved blood perfu-
sion and drug delivery (Provenzano et al, 2012; Jain et al, 2014;
Kirtane et al, 2017). Indeed, blood vessels of TNFa-CSG-treated
tumours when labelled by i.v. injection of FITC–lectin were signif-
icantly dilated compared to vessels in control CSG-treated or
TNFa-RGR-treated tumours (Figs 6A and EV5C). In addition,
whilst the treatment has no effect on CD31+ vessel numbers
(Fig EV5D), the overlay of lectin+ vessels with a CD31 stain, a
measure of tumour perfusion, was significantly enhanced in
TNFa-CSG treatment groups (Figs 6B and EV5E). There was an
inverse correlation between lectin staining and tumour collagen
IV content (Fig 6C), which is in agreement with earlier studies
showing that ECM degradation enhances tumour vessel perfusion,
presumably by decompression (Provenzano et al, 2012; Kirtane
et al, 2017).
To assess the impact of reduced tumour ECM on tumour perfu-
sion and the uptake of circulating compounds into tumours, we
measured transport of the gadolinium contrast agent gadoteridol
from the circulation into 4T1 tumours by dynamic contrast-
enhanced MRI (DCE-MRI) in real time in vivo. Gadolinium uptake
rate doubled in the TNFa-CSG-treated tumours as compared with
the CSG control (Fig 6D). Uptake of iron oxide nanoparticles
(IONPs) also increased in response to TNFa-CSG therapy, as shown
by T2* and T2 relaxation images (Figs 6E and EV5F). Increased
accumulation of IONPs in TNFa-CSG-treated tumours was also con-
firmed by immunohistochemistry (Fig 6F). Collectively, these data
show that reduced ECM content and cancer stiffness are associated
with enhanced tumour uptake of compounds ranging from small
molecules such as gadoteridol to nanoparticles.
TNFa-CSG enhances anti-tumour immune responses without
increasing metastasis
To study the potential therapeutic effects of TNFa-CSG, we first
assessed the survival of RIP1-Tag5 and 4T1 tumour-bearing mice. A
treatment regimen with 5 daily doses of 2–5 lg TNFa-CSG
prolonged the survival of these mice (Fig 7A and B), consistent with
reduced 4T1 tumour burden (Fig 7C) and cancer cell proliferation
(Ki67+ staining; Appendix Fig S3A), and increased apoptosis
(TUNEL+ cells; Appendix Fig S3B). Direct exposure of cultured 4T1
and RIP1-Tag5 tumour cells to TNFa-CSG, even at concentrations
sevenfold to 18-fold higher than estimated in vivo levels, did not
significantly reduce cell viability (Appendix Fig S3C). Thus, the
in vivo therapeutic data, along with evidence of high infiltration of T
cells in TNFa-CSG-treated tumours (Figs 3A and EV3C), suggest the
potential involvement of T cells in mediating anti-tumour immunity.
This prompted us to quantify cytotoxic (granzyme B+) T cells in
TNFa-CSG-treated 4T1 tumours. Indeed, TNFa-CSG therapy
increased the abundance of cytotoxic T cells but not immune-
suppressing regulatory (CD4+ CD25+ FOXP3+) T cells in the
syngeneic 4T1 tumour model (Fig 7D; gating strategies in
Appendix Fig S3D). To confirm the involvement of T cells in anti-
tumour immunity, we treated immunodeficient 4T1 tumour-bearing
BALB/c nude mice with TNFa-CSG in the absence or presence of
adoptively transferred naive splenic T cells (Fig 8A). In the absence
of T cells or in the presence of only CD4+ or CD8+ T cells, TNFa-
CSG treatment did not significantly reduce tumour weight and
volume (Fig 8B). However, TNFa-CSG treatment and adoptive
transfer of both CD8+ and CD4+ T cells (triple combination)
produced anti-tumour effects similar to those observed in syngeneic
4T1 tumour-bearing mice (Fig 8B). Similarly, tumours only showed
significant infiltration of T cells, ECM loss and inhibition of cell
proliferation under triple treatment (Fig 8C and D, and
Appendix Fig S3E). These data suggest both CD8+ and CD4+ T cells
are required for intratumoral TNFa-CSG effects.
An important consideration for any ECM-reducing strategy is the
potential risk of metastatic dissemination (Ozdemir et al, 2014;
Sevenich & Joyce, 2014; Schmaus & Sleeman, 2015; Rath et al,
2017). Appendix Fig S4A shows that TNFa-CSG-treated 4T1 tumours
were less hypoxic especially in areas containing wider blood
vessels, which reduces the likelihood of hypoxia-driven metastatic
dissemination (Rankin & Giaccia, 2016). We further assessed the
effect of TNFa-CSG on highly metastatic 4T1 tumour cells
(Appendix Fig S4B) which typically colonise in the lung from as
early as 19 days after orthotopic implantation in the mammary fat
◀ Figure 3. TNFa-CSG (T-CSG) treatment promotes immune cell infiltration and induces them to secrete proteases.A Left panels: Representative micrographs of immune cell infiltrates (red) in tumours from RIP1-Tag5 mice untreated (UT) or treated with 5 daily i.v. injections of
indicated compounds. Scale bars: 100 lm. Right panels: fraction of cells stained with the indicated antibodies/tumour and mean  SEM (4–7 tumours from n = 3
mice; *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 by one-way ANOVA test with Tukey’s correction).
B Quantitative RT–PCR analysis comparing protease expression in isolated CD45+ CD11b cells from 4T1 tumours of mice treated with 5 daily i.v. injections of indicated
compounds, relative to the expression of hypoxanthine-guanine phosphoribosyltransferase (HPRT) standard. Bar graphs showing means  SEM of the mRNA
expression for the indicated proteases (n = 4–5; *P < 0.05, **P < 0.005 and ***P < 0.001 when compared to CSG-treated group by multiple t-tests).
C Quantitative analysis of proteases in media of splenic T cells (CD4+ and CD8+) and CD11b+ cells isolated from C3H mice, after 4- and 20-h incubation with 0.1 lg CSG
or 1 lg TNFa-CSG. A 20-h incubation of untreated (UT) cells was also included as control. Each dot represents an individual sample, and mean  SEM is shown
(n = 4; *P < 0.05, ***P < 0.001 and ****P < 0.0001 by one-way ANOVA test with Tukey’s correction or Kruskal–Wallis test with Dunn’s correction for cathepsin L).
Horizontal dotted line indicates below the limit of detection.
Source data are available online for this figure.
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pad (Pulaski & Ostrand-Rosenberg, 2001). We treated mice bearing
4T1 tumours with a TNFa-CSG regimen that resulted in high expres-
sion of proteases (Fig 3B) and measured lung metastasis by colony
assays (Pulaski & Ostrand-Rosenberg, 2001). The treatment signifi-
cantly reduced dissemination of 4T1 cells from primary tumours to
the lungs (Appendix Fig S4C).
In summary, our findings show that treatment of tumour-bearing
mice with TNFa targeted to tumour laminin–nidogen complexes is
well tolerated and induces tumour infiltration of immune cells,
which in turn results in loss of tumour ECM, improved tumour
perfusion, reduced tumour burden and enhanced overall survival.
Discussion
We have constructed a recombinant TNFa fusion protein that
specifically localises to tumour laminin–nidogen complexes when
injected systemically into mice bearing desmoplastic tumours. By
eliciting an influx of immune cells into the tumours, the fusion
protein causes dramatic reduction in desmoplasia. The reduced
ECM content improves tumour perfusion, thus facilitating the
entry of circulating compounds, such as imaging agents into the
tumour. Treatment also suppresses tumour growth which is only
seen in immunocompetent mice, suggesting activation of adaptive
A
C D
B
Figure 4. TNFa-CSG treatment induces specific tumour ECM degradation.
Tumour sections from RIP1-Tag5 following treatment with 5 daily i.v. injections of indicated compounds were analysed for ECM expression.
A Staining with indicated antibodies (red) for tissues treated with 5 lg doses of TNFa-CSG (T-CSG) or TNFa-RGR (T-RGR), or 0.8 lg doses of CSG peptide. Scale bars:
50 lm.
B Quantitative analysis of ECM staining/field/tumour from panel (A) and mean  SEM (3–8 tumours from n = 3 mice; *P < 0.05 for 2 and 5 lg TNFa-CSG compared to
other groups by one-way ANOVA test with Tukey’s correction).
C Co-staining analysis of tumours (as in panel A) with collagen IV (ECM, red) and CD45 (immune infiltrate, green). Arrows: areas within tumour showing immune cells
in sites negative for collagen IV expression. Scale bars: 50 lm.
D Correlation analysis of % CD45+ cells and collagen IV+ areas/tumour from TNFa-CSG-treated RIP1-Tag5 mice (10 tumours from n = 3 mice; Spearman’s correlation,
r = 0.8788, **P = 0.0016).
Source data are available online for this figure.
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tumour immunity. These effects are achieved without systemic
toxicity.
The CSG peptide we used for tumour targeting has several char-
acteristics that distinguish it from other tumour-homing peptides.
Whilst most tumour-specific homing peptides (and antibodies)
target cell surface proteins specifically expressed on tumour vascula-
ture or tumour cells, we selected CSG for ECM targeting. In the few
cases where ECM components have been targeted before, target
proteins such as tumour-specific variants of the ECM proteins fibro-
nectin and tenascin are primarily located around tumour blood
vessels (Borsi et al, 2003; Kim et al, 2012). In contrast, CSG and its
payload appear to penetrate into tumours reaching sites far from the
blood vessels. In this regard, CSG resembles the previously discov-
ered CendR-type tumour-penetrating peptides, which activate an
A B
E
C D
Figure 5. TNFa-CSG treatment reduces tumour stiffness.
Stiffness analyses of the 4T1 tumours following treatment with 4 × daily i.v. injections of indicated compounds. Tumour stiffness was analysed on day 5.
A En face optical coherence tomography (OCT) images of tumours at a depth of ~100 lm. Scale bars: 1 mm.
B The corresponding en face quantitative micro-elastograms showing tumour elasticity. Scale bars: 1 mm.
C Plots of stiffness distribution in the tumours.
D Top: Stiffness variance (see Materials and Methods). Bottom: Fractions of pixels between 100 and 1,000 kPa. For both plots, mean  SEM is shown (n = 3; *P < 0.05
by Student’s t-test).
E Collagen IV staining (purple = collagen) of whole tissue sections. Scale bars: 1 mm and 100 lm. Selected regions (x and y in B and E) were compared for collagen IV
staining at higher magnification (E) and the corresponding micro-elastograms (B).
Source data are available online for this figure.
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endocytic transcellular and transtissue transport pathway
(Ruoslahti, 2016). Interestingly, the CSG sequence, CSGRRSSKC,
does contain a potential CendR motif (RSSK), but it remains to be
seen whether the CendR transport pathway is responsible for the
tumour-penetrating properties of CSG.
The molecular structure in ECM recognised by CSG may be
universal to tumours since all mouse and human tumours anal-
ysed so far showed specific and strong CSG homing or binding.
The laminin–nidogen complex we identified as the target of CSG is
a major constituent of all basement membranes, which also
A
C
E
F
D
B
Figure 6.
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include collagen IV and perlecan (Aumailley et al, 1993). In
normal tissues, these complexes are restricted to a thin basement
membrane that supports vessels and epithelia, whereas, in
tumours, an extensive network is formed throughout the tumour
that is not associated with blood vessels. There is a clear quantita-
tive difference in the amount of ECM; in the cancers we studied,
tumours expressed twofold to 10-fold more ECM than the corre-
sponding normal tissue. This difference, at least at the lower end,
does not entirely explain the lack of CSG homing/binding to
normal tissues. Importantly, CSG binds to both stroma-associated
ECM and ECM secreted by neoplastic cells. These findings raise
the possibility of a structural difference in tumour ECM compared
to normal ECM that allows CSG binding. As tumour ECM
complexes are expressed in an aberrant manner, it could also be
disorganised, exposing a normally hidden epitope. Such a situation
has been described in collagen I of fibrotic lungs (Desogere et al,
2017). In this scenario, collagen I is overproduced and assembled
into disorganised fibrils, which in turn exposes binding sites for a
specific peptide probe.
Our CSG-based targeting strategy was employed to achieve high
levels of TNFa locally and specifically associated with tumour
ECM. In contrast, untargeted TNFa is highly toxic when adminis-
tered systemically (Cauwels et al, 1995; Marino et al, 1997; Leje-
une et al, 2006). Moreover, the biological effects of TNFa targeted
to tumour ECM were different from those of TNFa targeted to
tumour vessels (Johansson et al, 2012). Targeting TNFa to tumour
ECM has some major benefits: first, the amount of ECM compo-
nents is high relative to binding moieties in blood vessels or
tumour cells, making the targeting particularly effective. Second,
TNFa-CSG enables selective modulation of the matrix. Abundant
ECM in cancer represents a physical barrier for drug delivery, and
the ECM also provides a supportive environment for tumour
growth (Hellebust & Richards-Kortum, 2012; Salmon et al, 2012;
Choi et al, 2013). Moreover, particularly in highly desmoplastic
tumours, ECM is extensively remodelled to form harder and stiffer
tissue than the normal counterpart tissues (Mouw et al, 2014;
Pickup et al, 2014). Increased ECM content and stiffness exerts
a mechanical compressive force within the tumour
microenvironment, causing the vessels within the tumour to
collapse (Jain et al, 2014). Therefore, ECM degradation releases
the stresses and is considered an efficient strategy for tumour
blood vessel decompression which in turn enhances tumour perfu-
sion and access of circulating compounds (Provenzano et al, 2012;
Jain et al, 2014; Rahbari et al, 2016; Kirtane et al, 2017).
Systemic delivery of ECM-degrading enzymes such as PEGPH20
(pegylated hyaluronidase) has been used to degrade tumour ECM
components for the purpose of enhancing perfusion and access to
solid tumours (Guedan et al, 2010; Provenzano et al, 2012; Caruana
et al, 2015; Rahbari et al, 2016; Kirtane et al, 2017). The TNFa-CSG
strategy differs from these approaches in that the ECM reduction
following TNFa-CSG therapy is a result of immune cell infiltration
and local production of a cocktail of ECM-degrading proteases by
these immune cells. The ECM depletion effects by TNFa-CSG
include the loss of laminin, nidogen-1, collagen IV, collagen I, fibril-
lar collagen, fibronectin, perlecan and potentially fibroblasts which
are positive for ER-TR7. Whilst our data clearly indicate that TNFa-
CSG can remove ECM components in advanced tumours, one limita-
tion of this study is that the potential suppressive effect by TNFa-
CSG on tumour fibroblasts, and their secretion of ECM components
was not addressed.
We show that ECM reduction by TNFa-CSG alleviates tumour
stiffness, reduces vessel compression, increases vessel dilation and
may facilitate further increases in immune cell infiltration. Similar
to what has been shown for other ECM-reducing strategies (Proven-
zano et al, 2012; Kirtane et al, 2017), TNFa-CSG enhanced tumour
perfusion and uptake of MRI contrast agents, indicating potential
use for cancer imaging. Currently, clinical MRI detection of cancer
and differentiation from normal tissues are based on differences in
vascularity, vessel permeability and extracellular diffusion space
(Kinkel & Hylton, 2001; Wang, 2011). IONPs, including particles
marketed as Feridex and Resovist, failed commercially as MRI
contrast agents. Their poor performance, as indicated in our find-
ings and others (Wang, 2011), is partly because IONPs do not pene-
trate into solid tumours. Here, we show that TNFa-CSG therapy
improves the tumour accumulation of IONPs. Thus, TNFa-CSG
treatment prior to imaging could potentially sensitise the tumours
◀ Figure 6. ECM depletion in TNFa-CSG-treated tumours (T-CSG) correlates with decompressed blood vessels, and enhanced perfusion and uptake ofnanoparticles.
A Lectin+ vessels (green) in tumours after RIP1-Tag5 mice were treated with 5 daily i.v. injections of indicated compounds (or untreated, UT) and perfused with
fluorescein-labelled lectin. Representative micrographs show lectin+ vessel widths for each group, and quantification of mean vessel diameter/tumour area and
mean  SEM are shown (12–15 tumours from n = 5 mice; ****P < 0.0001 for TNFa-CSG compared to control groups by one-way ANOVA test with Tukey’s
correction). Scale bars: 100 lm.
B Co-staining of lectin-perfused RIP1-Tag5 tumours (as in panel A) with CD31 (red, blood vessels). Left: Micrographs show co-localisation (yellow) of perfused lectin and
CD31 staining in tumours. Scale bars: 50 lm. Right: Data show lectin:CD31 ratio for individual tumours and mean  SEM (5–7 tumours from n = 3 mice; *P < 0.05,
****P < 0.0001 by one-way ANOVA test with Tukey’s correction).
C Left: Representative tumour sections (as in panel A) show lectin+ vessel and co-stained collagen IV (red). Scale bars: 50 lm. Right: Correlation analysis of lectin+ and
collagen IV+ staining for all tumours irrespective of treatment (Pearson correlation, r = 0.5427, **P = 0.0028).
D Real-time measurement of 4T1 tumour uptake of gadolinium tracer. Top: Average gadolinium concentration after a bolus i.v. injection of 0.3 lmol/g gadoteridol was
measured by T1-weighted MRI and plotted against time after mice were treated with indicated compounds. Bottom: The rate constant, K1, representing permeability
into the tumour (see Materials and Methods) is plotted for individual mice and mean  SEM (n = 4–5; *P < 0.05 by Student’s t-test).
E Left: Ex vivo MRI scans of T2* (dark contrast) and T2 relaxation (magenta) show detectable amounts of IONP in tumours 4 h after an i.v. injection of 5 mg/kg IONP in
RIP1-Tag5 mice treated as in panel (A) (arrow: tumour nodule). Scale bars: 1 mm. Right: Reduction in T2 relaxation time indicates the relative amount of IONP in
individual tumours and mean  SEM (5–10 tumours from n = 3 mice; ****P < 0.0001 by Student’s t-test).
F Left: Micrographs show detection of IONP in RIP1-Tag5 tumours based on immunostaining with anti-FITC-HRP antibody. Scale bars: 400 lm and 200 lm for higher
magnification images. Right: Plots of IONP in individual tumours detected by reactivity with anti-FITC-HRP and mean  SEM are shown (6–9 tumours from n = 3
mice; *P < 0.05 by Student’s t-test).
Source data are available online for this figure.
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for improved accumulation of contrast agents, enabling better MRI
contrast.
The immune-enhancing effects of TNFa-CSG translated into ther-
apeutic benefits as shown by reduced tumour growth and enhanced
survival in tumour-bearing mice with an intact immune system.
Importantly, this was not the case in mice with a compromised
adaptive immune system. TNFa-CSG therapy was ineffective in
BALB/c nude mice, and transfer of normal CD8+ and CD4+ T cells
into these mice restored the ECM degradation and anti-tumour
effects. These findings show that the TNFa-CSG effects are primarily
mediated by enhanced T-cell accumulation in solid tumours. These
cells included effector T cells (granzyme B+ CD8+), which are
indicative of anti-tumour immunity (Russell & Ley, 2002; Hoves
et al, 2012).
A
D
B C
Figure 7. TNFa-CSG therapy enhances survival, suppresses tumour growth and generates intratumoral effector T cells.
A, B Per cent survival of mice bearing RIP1-Tag5 and 4T1 tumours, either untreated or treated according to the schedule depicted (n = 16–27 for RIP1-Tag5 and n = 5
for 4T1; **P < 0.001 and ***P < 0.0005 by log-rank Mantel–Cox test).
C 4T1 tumour-bearing mice were left untreated (UT) or treated with indicated compounds according to treatment schedule shown in panel (B). Top panel:
Photographic images of excised 4T1 tumours from each treatment group. Bottom panel: Plots of individual tumour volumes (mm3) and mean  SEM on day 18 are
shown (n = 5–11; **P < 0.01 by one-way ANOVA test with Tukey’s correction).
D Left: Representative flow cytometry plots of cytotoxic (Granzyme B+) CD8+ and CD4+ T cells and regulatory (CD25+, FoxP3+) CD4+ T cells isolated from 4T1 tumours
of mice treated with 5 daily i.v. injections of CSG or 2 lg TNFa-CSG (gating strategies in Appendix Fig S3D). Graphs show mean  SEM fractions of cytotoxic CD8+
and CD4+ T cells and regulatory CD4+ T cells in each treated tumour (n = 5; *P < 0.05 and ***P < 0.001 by Student’s t-test).
Source data are available online for this figure.
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The ECM content and stiffness have been shown to influence the
metastatic potential of tumours. For instance, stiff cancers can
induce the expression of adhesion molecules which facilitate tumour
cell adherence and transmigration through microvascular endothe-
lia. Reducing these adhesive interactions by ECM degradation can
thus be expected to prevent or reduce metastasis (Rath et al, 2017;
Reid et al, 2017; Vennin et al, 2017). However, ECM degradation
has also been shown to increase the release of tumour cells into the
circulation, promoting metastasis (Sevenich & Joyce, 2014; Brown &
Murray, 2015; Schmaus & Sleeman, 2015). Our data suggest that
TNFa-CSG treatment, despite the resulting ECM loss, does not
increase metastasis, potentially because it reduces tumour hypoxia.
Metastasis often occurs under hypoxic conditions when tumour
oxygen supply is compromised (Rahbari et al, 2016; Rankin &
Giaccia, 2016).
TNFa is already a clinically approved agent (marketed by
Boehringer Ingelheim as BeromunR). Because of the toxicity of
TNFa, it is mainly applied locally, for instance in isolated limb
perfusion to treat advanced melanoma and sarcoma (Lejeune
et al, 2006). A few targeted TNFa compounds are in clinical
trials; a TNFa fusion to an NGR-motif peptide, which targets
tumour-associated aminopeptidase N (NGR-TNFa, Arenegyr;
MolMed), and an antibody-TNFa conjugate, which targets EDB
domain-containing fibronectin in tumours (L19-TNF, Fibromun;
Philogen), have entered multiple cancer trials (Gregorc et al,
2010; Spitaleri et al, 2013). However, these compounds primarily
target tumour vessels (Pasqualini et al, 2000; Borsi et al, 2003),
whereas our results show that CSG and its payload penetrate into
ECM in extravascular tumour tissue, possibly because it engages
the CendR transcytosis and transtissue transport pathway
(Sugahara et al, 2009; Teesalu et al, 2009).
In summary, TNFa-CSG has the dual capacity to promote
immune cell entry and ECM degradation within the tumour. Since
the effects on immune cell infiltration and ECM depletion are inter-
twined, there are several potential clinical applications for TNFa-
CSG in cancer treatment. For instance, pre-treatment with TNFa-
CSG may sensitise inaccessible tumours for better detection as
exemplified here by improved uptake of the nanoparticle contrast
agent. Whilst we have not investigated the immunotherapeutic
potential of TNFa-CSG, our findings suggest that TNFa-CSG may be
used to inflame tumours which lack intrinsic effector T cells, and its
full therapeutic potential could be achieved in combination
with immune checkpoint blockade or other immunotherapeutic
strategies.
A
C D
B
Figure 8. CD8+ and CD4+ T cells mediate ECM degradation and anti-tumour effects of TNFa-CSG.
A BALB/c nude mice bearing 4T1 tumours were treated with 5 daily i.v. injections of TNFa-CSG in the absence or presence of naïve splenic CD4+ and CD8+ T cells, or
both (triple treatment). The cells were injected i.p. on days 10 and 13. On day 16 post-implantation, the tumours were analysed for weight and volume (B), immune
infiltrates (C) and collagen IV content (D).
B Plots of individual tumour weights (g) and volumes (mm3) and mean  SEM on day 16 are shown for untreated (UT) and treated groups (n = 5; *P < 0.05 and
**P < 0.005 by one-way ANOVA test).
C Left: Micrographs show CD4+ and CD8+ T cells (purple) counterstained with methyl green in tumours from the indicated treatment groups. Scale bars: 40 lm. Right:
Bar charts show mean  SEM of CD4+ and CD8+ T-cell counts/field (n = 3; *P < 0.05 and **P < 0.005 by one-way ANOVA test with Tukey’s correction).
D Left: Micrographs show representative collagen IV (Col-IV) expression (purple) counterstained with methyl green in untreated and treated tumours. Scale bars: 25 lm.
Right: Bar charts show mean  SEM of collagen IV staining/field (n = 5; *P < 0.05 and ***P < 0.001 by one-way ANOVA test with Tukey’s correction).
Source data are available online for this figure.
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Materials and Methods
Cell lines
Murine cell lines, including 6-thioguanine-resistant 4T1 breast
cancer cells, colon carcinoma CT26 and MDA-MB-435 human carci-
noma, were purchased from ATCC. Mouse brain endothelial cells
(bEnd5) were kindly provided by B. Engelhardt (University of Bern,
Bern, Switzerland). bTC-C3H tumour cells were derived from RIP-
Tag mice bred on a C3H genetic background and were kindly
provided by D. Hanahan (Institute Suisse de Recherches Experimen-
tales sur le Cancer, Lausanne, Switzerland).
Tumour-bearing mice
All mice were kept under specific pathogen-free conditions, and all
experimental protocols were approved by the Animal Ethics Commit-
tees of the University of Western Australia (UWA), Sanford Burnham
Prebys Medical Discovery Institute (SBP) and University of Califor-
nia, Davis (UCDavis). All mice were kept under specific pathogen-
free facilities at UWA, SBP and UCDavis with food and water
provided ad libitum. RIP1-Tag5 transgenic mice were established on
a C3HeBFe background (kindly provided by D. Hanahan). Both male
and female RIP1-Tag5 mice at 25–29 weeks of age were used in all
studies. ALB-Tag transgenic mice were established on a C3HeBFe
background and spontaneously develop hepatocellular carcinoma at
9 weeks of age. Both male and female ALB-Tag mice at 10–12 weeks
of age were used in all studies. MTV-PyMT+ mice were established
on C57BL/6 background. Only 8-week-old female mice were used in
the homing study. Unless otherwise stated, transplanted murine
tumours were inoculated with 5 × 105 cells either orthotopically into
mammary fat pad (4T1 and MDA-MB-435 cells) or subcutaneously
(CT26 cells) in 9- to 12-week-old female mice, either syngeneic
BALB/c (for 4T1 and CT26) or nude BALB/c (for MDA-MB-435 and
4T1). For adoptive transfer experiments, splenic CD4+ and/or CD8+
T cells isolated by MACS cell separation (Miltenyi Biotec) were
injected into total of 2.5 × 106 cells per i.v. injection. All mice were
randomly assigned to various experimental groups.
Phage display
In vitro phage display was performed by incubating the phage library
(3.7 × 1010 plaque-forming units (p.f.u.) onto MatrigelTM-coated tissue
culture wells at 4°C overnight, and unbound phages were removed by
serially washing with 1% BSA in DMEM. The bound phage was quanti-
fied by titration. The enriched phage pool from three rounds of in vitro
biopanning on MatrigelTM was then subjected to four rounds of in vivo
selection by injecting the Matrigel-selected library (1.7 × 109 p.f.u.) into
the tail vein of a BALB/c nude mouse bearing an MDA-MB-435 tumour
followed by perfusion of the circulatory system and quantification of
the bound phage in target organs by titration (Teesalu et al, 2012). Indi-
vidual clones derived from this in vivo-selected tumour-homing pool
were picked, and their peptide-encoding inserts were sequenced.
Peptide synthesis
Peptides, amidated at the C-terminus, were synthesised on a
microwave-assisted automated peptide synthesiser (Liberty; CEM,
Matthews, NC) following Fmoc/tertiary butyl strategy on rink amide
MBHA resin with HBTU (N,N,N0,N0-tetramethyl-O-(1H-benzotriazol-
1-yl)uronium hexafluorophosphate) activator (or alternatively, O-
(benzotriazol-1-yl)-N,N,N0,N0-tetramethyluronium hexafluorophos-
phate), collidine activator base and 5% piperazine for deprotection.
When included, fluorescein was incorporated during the synthesis
at the N-terminus of the sequence as 5(6)-carboxyfluorescein with a
spacer, 6-aminohexanoic acid, separating the fluorophore and the
sequence. All the peptides were purified to purities > 90% by HPLC
with acetonitrile and water gradient mixtures with 0.1%TFA.
Peptides were analysed by MALDI and found to have [M+H]
1022.9 for Ac-CSG, 1451.853 for FAM-CSG, 1612.17 for FAM-
ARALPSQRSR (FAM-ARA) and 1076.244 for FAM-CREKA.
Production of recombinant proteins
Recombinant TNFa was produced as described previously
(Johansson et al, 2012). Briefly, mature murine TNFa with or with-
out a C-terminal-modified CSG peptide (CSGRRSSKC, connected via
a GGG linker) was cloned into Xho/BamH1 sides of the vector pET-
44a (Novagen) to express soluble fusion proteins with N-terminal
Nus•Tag/His•Tag. Briefly, after isopropyl-b-D-glactopyranoside
(IPTG) induction overnight at 25°C, cultures were centrifuged,
resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl,
10 mM imidazole, 1 mM DTT, 1 mM PMSF, 1 mM EDTA and 1%
Triton X-100 (vol/vol) at pH 8.0), incubated with 1 mg/ml lysozyme
on ice for 30 min, sonicated and purified using Ni-NTA beads (Qia-
gen) according to the manufacturer’s instructions. Nus•Tag/His•Tag
was cleaved with tobacco etch virus (TEV) protease at 30°C for 6 h.
Recombinant proteins from cleavage reactions were dialysed over-
night in PBS and purified by using Ni-NTA beads. Purity was
assessed on Coomassie Brilliant Blue-stained protein gels. The
recombinant TNFa-CSG and unconjugated TNFa are approximately
18.9 and 17.7 kDa.
In vitro and in vivo peptide binding
Peptide binding in vitro was assessed by incubating 5 lM FAM-CSG,
FAM-ARA or FAM-CREKA on 8-lm tissue cross-sections for 30 min,
and tissues were analysed by microscopy. For in vivo biodistribution
analysis, tumour-bearing mice were injected intravenously (tail
vein) with 100 ll of 1 mM FAM-CSG or FAM-ARA. After 1 h,
animals were euthanised and tissues, including tumour, heart, liver,
spleen, kidney, skin, muscle, brain, lung, small intestine, vertebrae
and pancreas, were excised and imaged under a UV illuminator
(Illumatool, Lightools Research, CA, USA) for green fluorescence
intensity. Tissues were embedded in O.C.T. (Tissue-Tek) as fresh
frozen and stored at 80°C for further histology analysis.
Peptide binding on human tissues
All experimental protocols were approved by Human Ethics
Committees of the University of Western Australia and Sir Charles
Gairdner Hospital. Informed consent was obtained from all subjects
and that the experiments conformed to the principles set out in the
WMA Declaration of Helsinki and the Department of Health and
Human Services Belmont Report. Breast tumour and adjacent
samples > 1.5 cm were obtained as fresh and unfixed specimens
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within 1 h post-mastectomy from consenting n = 7 breast cancer
patients. The breast cancer biopsies were classified as stage 2–3
(grade 3) carcinoma (n = 2) and invasive ductal carcinoma (n = 2),
all within 35–50 mm in diameter. The patients did not receive any
treatment prior to the mastectomy. Pancreatic ductal carcinoma
(PDAC) samples were obtained from n = 3 untreated patients
following pancreaticoduodenectomy. Hepatocellular carcinoma
(HCC) samples were obtained from n = 3 HCC patients undergoing
hepatectomy. In binding studies, acetone-fixed serially cut 8-lm
tissue sections of untreated specimens were first blocked with 5%
BSA solution and incubated with 1 lM FAM-CSG or control FAM-
ARA for 30 min, and washed three times with PBS for 5 min. In
CSG blocking studies, the tissue sections were pre-incubated with
1 mM unlabelled CSG peptide for 20 min prior to incubation with
FAM-CSG. Peptide binding was determined based on the tissue reac-
tivity to anti-FITC-HRP antibody.
Affinity chromatography for receptor isolation
Matrigel extract at 0.5 mg/ml in buffer containing 50 mM Tris,
5 mM EDTA-Na and protease cocktail inhibitor (Thermo Scientific)
was incubated with CSG-coated Sulfolink beads (Pierce Biotechnol-
ogy) at 4°C. After washing, bound proteins were eluted with the
same buffer containing 2 mmol/l free CSG or CREKA peptide and
separated by sodium dodecyl sulphate–polyacrylamide gel elec-
trophoresis. Gel bands excised from silver-stained gels were
digested, and peptides were extracted as described previously
(Bringans et al, 2008). Samples were analysed an Agilent 6540 Q-
TOF mass spectrometer (Agilent Technologies) with an HPLC Chip
Cube source. The analyses were performed in the WA Proteomics
Facility, supported by Lotterywest and Bioplatforms Australia, at the
Harry Perkins Institute for Medical Research.
TNFa-CSG homing and treatment studies
To investigate intratumoral accumulation of TNFa-CSG, 100 lg of
FITC-labelled TNFa-CSG or TNFa (via amine-reactive NHS–fluores-
cein conjugation, Thermo Scientific) was i.v. injected into tumour-
bearing mice. After 1 h, animals were euthanised and tissues,
including tumours, heart, liver, kidney and pancreas, were excised,
embedded in O.C.T. and stored at 80°C for further histological
analysis. In treatment studies, RIP1-Tag5 and 4T1 tumour-bearing
mice were i.v. injected with PBS, CSG, TNFa, TNFa-CSG or TNFa-
RGR at required doses. Analyses of lectin and IONP uptake, FACS,
micro-elastography and DCE-MRI were done within 24 h after final
treatment was administered to the tumour-bearing mice, unless
otherwise stated.
Lectin perfusion and hypoxia assessment
For lectin perfusion, the mice were i.v. injected with 100 lg of
FITC-labelled tomato lectin (Lycopersicon esculentum; Vector).
After 10 min of circulation, mice were heart-perfused with 2%
neutral-buffered formalin (w/v) and tumours were frozen in O.C.T.
compound. To evaluate tumour hypoxia, mice were i.v. injected
with 1.5 mg pimonidazole (HydroxyprobeTM-1). Tissues were
collected after 1-h circulation, fixed with 2% neutral-buffered forma-
lin and frozen in O.C.T. after 2 h in 10 and 30% sucrose gradients.
Histology analysis
Tissue distribution of fluorescein (FAM/FITC)-labelled peptides
and recombinant proteins was detected on 8-lm tissue cross-
sections (prepared from O.C.T. embedded tissues) based on
their fluorescence intensity and reactivity to anti-FITC-HRP anti-
body (polyclonal, Gentex, 1:300) and counterstained with
haematoxylin or methyl green (Vector Laboratories). For
immunohistochemistry, the following antibodies were used: anti-
CD8a (53-6.7; eBioscience, 1:100), anti-CD4 (GK1.5; eBioscience,
1:50), anti-CD45 (30-F11, eBioscience, 1:100), anti-CD31 (390;
eBioscience, 1:100), anti-CD106 (VCAM-1, 429; eBioscience,
1:100), anti-collagen IV (polyclonal; Abcam, 1:200), anti-CD11b
(M1/70; BD Pharmingen, 1:100), anti-nidogen-1 (ELM1; Milli-
pore or polyclonal; R&D Systems, 1:50), anti-laminin (poly-
clonal; Millipore, 1:300), anti-fibronectin (polyclonal; Abcam,
1:100), anti-heparan sulphate proteoglycan 2 or perlecan (A7L6;
Abcam, 1:100), anti-collagen I (polyclonal; Abcam, 1:500), ER-
TR7 (murine thymic reticulum; Abcam, 1:100) and anti-Ki67
(SolA15; eBioscience, 1:100). For secondary detection, Vector
VIP Peroxidase Substrate Kit (Vector Laboratories) as well as
fluorescence-labelled, Alexa Fluor 488- or 594-conjugated anti-
rat, and anti-rabbit or anti-goat (Life Technologies) were used.
Tissues from pimonidazole-injected mice were stained with anti-
pimonidazole (HydroxyprobeTM-1) based on the product standard
protocol. Trichome connective tissue staining, picrosirius red stain-
ing (Abcam) and TUNEL assay (Sigma) were performed as per
product protocol. Images were captured on a Nikon Ti-E micro-
scope (Nikon Instrument Inc, N.Y., USA) or ScanScope XT (Aperio
Technology, Inc, CA, USA). Image analysis and quantification were
performed using either NIS software modules (version 4.0) or
ImageScope version 12.1.0.5029 (Aperio Technology, Inc, CA,
USA).
Isolation of immune cells and flow cytometry analysis
4T1 tumours were excised from CSG and TNFa-CSG-treated mice,
minced and incubated in DMEM high-glucose medium containing
0.1 mg/ml DNase I (Sigma) and 0.5 mg/ml collagenase IV (Sigma)
for 1 h at 37°C under gentle rotation. The cell suspension was
passed through a 70-lm membrane and subsequently washed with
FACS buffer [1% BSA (w/v, Sigma) in PBS]. For analysis of immune
cells, viable cells (Zombie AquaTM selection; BioLegend) were
stained with the following antibodies: CD45-APC-efluor 780 (30-
F11; eBioscience, 1:200), CD3-BUV395 (145-2C11; BD, 1:200), CD4-
BV510 (Gk1.5; BD, 1:100), CD8-PE-CF594 (53-6.7; BD, 1:300),
CD11b-PE (M1/70; BD, 1:300), F4/80-AF647 (BM8; BioLegend,
1:300) and Ly6G-FITC (1A8; BD, 1:100). For analysis of cytotoxic
and regulatory T cells, viable cells were stained with the following
antibodies: CD3-APC-eFluor 780 (145-2C11; eBioscience, 1:200),
CD4-FITC (Gk1.5; eBioscience, 1:200), CD8-PerCp-eFluor 710 (53-
6.7; eBioscience, 1:200), CD25PE-efluor 610 (PC61.5; eBioscience,
1:100), FoxP3-AF647 (150; BioLegend, 1:100) and granzyme B
(GB11; BD, 1:100). For intracellular staining (granzyme B and
FoxP3), cells were permeabilised with True-NuclearTM Transcription
Factor Buffer (Biolegend). Cells were sorted on a BD SORP Fortessa
and analysed on BD FACSDiva software version 8.0.1 (BD Bios-
ciences, USA).
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Protease gene expression analysis of tumour-infiltrating
immune cells
4T1 tumours were excised from CSG and TNFa-CSG-treated mice,
minced and incubated in DMEM high-glucose medium containing
0.1 mg/ml DNase I (Sigma) for 30 min at 37°C under gentle rotation
and passed through a 70-lm membrane. CD45+/CD11b+ and
CD45+/CD11b cells were sorted on a FACS Aria II (BD Bios-
ciences), and RNA from each sample was prepared using the RNA
Easy Mini Kit (Qiagen). For cDNA synthesis and qPCR, the RT2
system (Qiagen) was used according to the manufacturer’s protocol.
The gene expression profiles for urokinase plasminogen activator
(uPA), matrix metalloproteinases (MMPs, including MMP2, MMP3,
MMP9, MMP12 and MMP14), cathepsins (B, L, S and C) and
ADAMs (8, 9, 10 and 17) were assessed using a Q-PCR Kit (Qiagen)
on the Rotor-Gene Real-Time PCR Detection System. All reactions
were normalised to hypoxanthine-guanine phosphoribosyltrans-
ferase (HPRT). Primer sequences include uPA F (CGATTCTGGAG
GACCGCTTA), uPA R (GATTGAATCCAGTCCAGGAAGT), MMP2 F
(CCTGGACCCTGAAACCGTG), MMP2 R (TCCCCATCATGGATTC
GAGAA), MMP3 F (CCCCTGATGTCCTCGTGGTA), MMP3 R (GCA
CATTGGTGATGTCTCAGGTT), MMP9 F (GGACCCGAAGCGGACAT
TG), MMP9 R (GAAGGGATACCCGTCTCCGT), MMP12 F (ATGTG
GAGTGCCCGATGTACA), MMP12 R (AAGTGAGGTACCGCTTCA
TCCAT), MMP14 F (CATCATGGCCCCCTTTTACC), MMP14 R
(CGATCGTCATCAGGCAACAC), cathepsin B F (TTTGATGCACGGG
AACAATG), cathepsin B R (TTGGTGTGAATGCAGGTTCG), cathep-
sin C F (AAATGAGCCTGCGAGATCTGA) cathepsin C R (ATTGA
CGCCTTGGACGTTTC), cathepsin L F (AATACAGCAACGGGCA
GCA), cathepsin L R (AGCGGTTCCTGAAAAAGCCT), cathepsin S F
(CGCCAGCCATTCCTCCTT), cathepsin S R (ATGATTCACATTG
CCCGTACA), ADAM 8 F (CACCACTCCCAGTTCCTGTT), ADAM 8 R
(AAGGTTGGCTTGACCTGCT), ADAM 9 F (CCTTGCCTCTCTGCG
ACTAA), ADAM 9 R (AATTTCATAAGAAGAAAGATGGACAG),
ADAM 10 F (TTATGCCATGTTTGCTGCATGA), ADAM 10 R
(ACCACTGAACTGCTTGCTCCAC), ADAM 17 F (CAGCAGCACTCCA
TAAGGAA) and ADAM 17 R (TTGTGAAAAGCGTTCGGTA).
Measurement of protease levels
Spleens were excised from RIP1-Tag5 mice, minced and incubated
in RPMI for 30 min at 37°C under gentle rotation and passed
through a 70-lm membrane. CD4+ and CD8+ T cells and
CD11b+ monocytes/macrophages were isolated by MACS cell
separation (Miltenyi Biotec). Cells (300,000 cells/well) were
seeded onto Matrigel embedded with 0.4 lg CSG or 1 lg TNFa-
CSG, and were incubated with TexMACSTM (Miltenyi Biotec, T
cells only) or RPMI (monocytes). The levels of proteases secreted
in the supernatant at 4 and 20 h after seeding were measured by
ELISA following the manufacturer’s instructions. ELISA kits used
include mouse MMP9 (BosterBio), MMP12 (Abcam) and cathepsin
L (Cloud-Clone Corp).
Measurement of plasma CRP
Healthy C3H mice were treated with either (i) a single injection
of PBS, TNFa-CSG or TNFa or (ii) 5 daily injections of TNFa-CSG
or CSG at required doses. Plasma samples were collected
retro-orbitally, 5 h after a single-dose treatment and 48 h after the
mice were treated with 5 daily doses of TNFa-CSG and CSG.
Measurement of plasma CRP was performed by the PathWest Clini-
cal Biochemistry Laboratory, Queen Elizabeth II Medical Centre.
Plasma CRP was measured on a routine clinical chemistry analyser,
Abbott Architect c16000, by immunoturbidimetry, with a detection
limit of 0.2 mg/l and a measuring range of 0.2–480 mg/l (Abbott
Laboratories, Abbott Park, Illinois).
4T1 lung metastasis assay
Spontaneous 4T1 lung metastases in response to TNFa-CSG and
CSG treatment were measured following a published procedure
(Pulaski & Ostrand-Rosenberg, 2001). Briefly, on day 19 post-inocu-
lation (in which most tumours in CSG-control group reached the
ethical size endpoint of 1,500 mm3), 0.7 ml blood samples, lungs,
liver and sentinel lymph nodes were removed from TNFa-CSG and
CSG-treated tumour-bearing mice. Tissues were finely minced and
digested in 1× HBSS containing 1 mg/ml collagenase IV and 6 U/ml
elastase for 75 min at 4°C under gentle agitation. Digested cells were
washed, filtered and plated in serial dilutions on 10-cm culture
dishes containing growth medium and 60 lM 6-thioguanine. After
10 days, 6-thioguanine-resistant colonies were fixed in methanol
and stained with 0.03% (w/v) methylene blue. Methylene blue+
cells were imaged on a Nikon Ti-E microscope. For each sample, the
average fraction of 4T1 cells+/field of view from a minimum of 15
fields of view was quantified using NIS software modules (version
4.0).
Quantitative micro-elastography
Freshly isolated 4T1 tumours from mice treated with TNFa-CSG
were subjected to quantitative micro-elastography, an optical
coherence tomography (OCT)-based elastography method
described previously (Kennedy et al, 2014, 2015a,b) to produce
maps of the stiffness of a tissue with microscale resolution. The
imaging system comprises a custom-built OCT system and a piezo-
electric actuator-based mechanical loading apparatus. The spectral-
domain OCT system operates at a central wavelength of 840 nm,
with a measured axial resolution of 8 lm and a measured lateral
resolution of 11 lm. Each tumour was covered with a transparent
compliant silicone layer with known mechanical properties
(P7676, Wacker, Germany) and compressed between a glass
window and a compression plate. A piezoelectric ring actuator
(Piezomechanik, Germany), affixed to the imaging window, was
used to apply a force (1–10 newtons) to the tissue. The force
induced a micrometre-scale deformation within the sample, and
the axial component of this deformation was measured using
phase-sensitive OCT. Local axial strain at each location with the
OCT field of view was calculated as the change in axial displace-
ment with respect to depth over 100 lm within the tissue. The
stress imparted at the tissue surface by the actuator was estimated
by measuring the strain in the compliant layer and converting it to
stress via a stress/strain look-up table for the silicone material. Maps
of tumour stiffness, E, were generated by dividing the local stress, r,
by the local strain, e, i.e., E = r/e. Stiffness variance, a measure-
ment of the spread of tumour stiffness (range from 1–1,000 kPa),
was calculated as the average squared deviation of each number
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from its mean
P
ðxlÞ2
N
 
where x = stiffness of individual pixel,
l = mean of stiffness, and N = total number of pixels).
In vivo DCE-MRI
4T1 tumour-bearing mice, treated with TNFa-CSG or CSG, were
scanned on a Bruker BioSpec 70/30 (7T) small animal scanner
(Bruker BioSpin MRI, Ettlingen, Germany). Gadoteridol (Bracco,
Singen, Germany) was administered approximately 90 s after the
start of the scan (0.3 lmol/g, i.v. bolus), and data were collected
for ~10–15 min. Data were acquired, and images were recon-
structed using ParaVision 5.1 (Bruker BioSpin MRI) as previously
described (Thorsen et al, 2013). Parametric images were gener-
ated with either ParaVision 5.1 or MATLAB (MathWorks). A T1
map (RAREvtr: echo time (TE) = 22 ms; repetition time
(TR) = 5,000, 3,000, 1,500, 1,000, 800, 500, 365 ms; field of view
(FOV) = 1.8 × 3.6 cm2; matrix (MTX) = 64 × 128; slice thickness
(ST)/slice interval (SI) = 1 mm/1 mm; and 9 slices) was
performed prior to the administration of gadolinium contrast for
later use in deriving the gadolinium contrast agent concentration
from the MR signal intensity. A series of T1-weighted gradient-
echo images was acquired (FLASH; TE/TR/flip angle (FA):
2.7 ms/100 ms/30°; FOV = 4 × 2 cm; matrix = 160 × 80; 11
slices; and 100 repetitions) with a temporal resolution of 8 s. A
ROI was drawn around the tumour, and the mean signal intensity
versus time was converted to gadolinium concentration versus
time using: (i) a T1 map acquired prior to the DCE image series
and (ii) the previously measured relativity of gadoteridol in whole
mouse blood. The contrast agent versus time curve was used as
an input in a two-compartment pharmacokinetic model, and a fit
was obtained using pmod (PMOD Technologies Ltd, Zurich,
Switzerland) software.
Preparation of iron oxide nanoparticles (IONP)
Iron oxide (Fe3O4) was prepared by a precipitation method, as
described previously (Kang et al, 1996). The bare iron oxide was
then coated with dextran (MW 5,220, Sigma, St. Louis, MO, USA) as
described (Yu et al, 2012), generating particles of 13–18 nm in
diameter. Fluorescein lipid labelling was prepared by coupling 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-maleimide (DSPE-
PEG2000-maleimide, Avanti Polar Lipids) with carboxyfluorescein
(FAM) bearing a cysteine on its N-terminus in 1:1 molar ratio. The
dextran-coated iron oxides were encapsulated with PEGylated lipids
by combining dextran-coated iron oxides (in hexane) with DSPE-
PEG2000 and DSPE-PEG2000-FAM (in chloroform) in 1:1:0.37 molar
ratios (Sugahara et al, 2009; Starmans et al, 2013). The final coated
IONP was 33  3 nm in diameter (zeta potentials = 32.20 
2.26 mV), as measured by dynamic laser light scattering on a
Malvern Zetasizer Nano ZSP (Malvern, U.K.).
Ex vivo MRI and histological detection of intratumoral
IONP uptake
FAM-labelled IONP (5 mg/kg) were i.v. injected into 4T1 and
RIP1-Tag5 tumour-bearing mice treated with TNFa-CSG or CSG.
After 4-h in vivo circulation and heart perfusion with PBS to
remove circulating particles, tissues were collected and incubated
in 2% formalin for 2 h and embedded in 2% agarose. MRI scans
were performed at 9.4 T with a Bruker BioSpec 94/30 magnet,
Avance III HD console (Bruker BioSpin GmbH, Ettlingen,
Germany). Images were visualised by ParaVision 6.0.1 acquisition
software. Following a localiser, a series of three scans was
completed with 23 interleaved coronal slices: (i) a T2*-weighted
image [FLASH: echo time (TE) = 10 ms; repetition time
(TR) = 600 ms; flip angle (FA) = 30°; averages (NA) = 2; and
acquisition time (TA) = 3 min]; (ii) T2* map [MGE: TR = 1250 ms;
TE = 2.6 ms; FA = 90°; number of echoes (NE) = 10; echo spacing
(ESP) = 5 ms; TE (effective) = 2.6–47.6 ms; and TA = 5 min]; and
(iii) a T2 map [MSME: TR = 3150 ms; TE = 8 ms; FA = 90°; refo-
cussing pulse = 180°; NE = 16; ESP = 8 ms; and TA = 7 m 53 s].
For above scans, field of view (FOV) = 3.6 × 3.6 cm2, matrix
(MTX) = 240 × 240, slice thickness (ST) = 0.5 mm, and slice
gap = 25 lm. The T2* and T2 parameter maps for each tumour
were calculated from the MGE and MSME datasets, respectively,
using the ParaVision 6.0.1 macro fitinlsa that fits the signal for
each pixel according to a mono-exponential decay. Using the Image
Display and Processing Tool, tumour borders were segmented
manually using the track tool, based on the MSME image with TE
(effective) = 8 ms. Subsequently, the regions of interest (ROI) were
used in combination with the parameter maps to obtain statistics
on the T2* and T2 values for each ROI. Statistics for tumours were
obtained by combining the ROI statistics on an image slice by slice
basis. Tissue distribution of fluorescein-labelled IONPs was
detected on 8-lm tissue cross-sections based on their reactivity to
The paper explained
Problem
Most cancers are stiffer than normal tissue because they produce an
abundance of extracellular matrix (ECM), which forms a “barrier” for
drugs or immune cells. ECM depletion is a compelling strategy to
reduce tumour stiffness, decompress tumour blood vessels and thus
improve access of diagnostic and therapeutic agents, and anti-tumour
immune cells to the cancer core. However, it remains challenging to
ensure tumour ECM-targeting specificity with high local activity and
minimal toxicity to normal organs.
Results
In this study, we use a new biological agent, so-called TNFa-CSG, an
immune-modulating cytokine that is specifically targeted to tumour
ECM. The peptide-targeting moiety in this agent is highly specific for
mouse and human cancer ECM and does not bind to normal tissue.
TNFa-CSG treatment in pre-clinical cancer models attracts immune
cells which in turn secrete a cocktail of proteases and degrade ECM
locally. Reduced tumour stiffness and improved tumour perfusion
enhance tumour uptake of nanoparticles/imaging agents. Therapeuti-
cally, TNFa-CSG is highly effective by activating anti-cancer T cells
and suppresses tumour growth without systemic toxicity or increase
in metastatic activity.
Impact
This study demonstrates the local and selective activity of a new
ECM-targeting biological agent which reduces cancer stiffness and
increases perfusion. The novel combination of matrix depletion with
immune modulation facilitates drug and immune cell access into
fibrotic tumours and warrants clinical investigation.
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anti-FITC-HRP antibody (polyclonal, Gentex) and counterstained
with haematoxylin.
Statistical analysis
No statistical methods were used to predetermine sample size. A
minimum of 3 mice per group was used in all studies. However,
since each RIP1-Tag5 mouse usually carries multiple tumour
nodules (2–6 tumours/mouse), all graphs for RIP1-Tag5 mice show
data points from 2 to 6 tumours per mouse. For histological quan-
tification, raw data were obtained from each microscopically identi-
fied tumour on tissue section (2–4 identified tumours/tissue
sections). Raw data were obtained from at least three fields of view
for tumours > 3 mm or from the entire tumour section for tumours
< 3 mm. All studies were not blinded. For survival study of 4T1
tumour-bearing mice, age-matched animals with similar tumour
burden were randomised and treated in groups of 4–5 mice.
Survival of RIP1-Tag5 tumour-bearing mice was based on welfare
impact scores and independently evaluated as part of technical
service at the animal facility. Statistical analyses were performed
using GraphPad Prism 7 (GraphPad Prism Software, Inc.). Data
were analysed by Student’s t-test (two-tailed) or one-way analysis of
variance (ANOVA) unless indicated otherwise. Cumulative survival
time was calculated by the Kaplan–Meier method and analysed by
the log-rank test. A P value < 0.05 was considered statistically
significant. Error bars indicate SEM. Experiments were carried out
in an unblinded fashion.
Expanded View for this article is available online.
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